The world’s first cannabinoid-based antitumor Drug Candidate for the treatment of Colorectal Cancer based on our novel and proprietary formulation CNBX RCC-33
Proud to be a global leader in the development
of cancer & cancer related cannabinoid-molecule based therapeutic
formulations and medicines
CNBX Pharmaceuticals has been
conducting research on the antitumor effects of
cannabinoid formulations on cancer since its
establishment in 2012.
Yellow marker: dead cancer cells after 24 hrs.
CNBX Pharmaceuticals’ groundbreaking research and development is carried out in our in-house state of the art drug discovery facilities using proprietary High Throughput Screening (HTS) technology and advanced bioinformatics.
